Anjen Chenn
About Anjen Chenn
Current Title and Positions
Anjen Chenn holds the position of Medical and Scientific Director, and Discipline Director in Molecular Oncology at Labcorp. In these roles, Dr. Chenn oversees various programs and research initiatives within the field of molecular oncology. His work involves significant administrative and oversight responsibilities in addition to direct scientific contributions.
Education and Expertise in Molecular Oncology
Dr. Anjen Chenn holds both an MD and a PhD, positioning him with in-depth medical and scientific expertise. He specializes in molecular oncology, focusing his research and clinical efforts on understanding and treating cancers at the molecular level. His educational and professional background enables him to lead advanced research projects and contribute substantial developments in cancer treatment and diagnostics.
Research on Immunologic Factors in Cancer
Dr. Chenn has published research on the immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer. His work advances the understanding of how immune system factors influence treatment outcomes, aiming to improve therapeutic strategies for this aggressive cancer type.
Expertise in NK Cell ADCC Assays and Flow Cytometry
With his expertise in NK cell antibody-dependent cellular cytotoxicity (ADCC) assays and flow cytometry, Dr. Chenn contributes to the development and validation of diagnostic and therapeutic methods. These techniques are critical in understanding how immune cells can be harnessed or modulated to fight cancer.
Validation of Genomic Profiling Assays
Dr. Chenn has worked on the validation of comprehensive genomic profiling assays for hematologic malignancies. His research ensures the accuracy and reliability of genomic profiling tests, which are essential for the diagnosis and treatment planning of various blood cancers.
Research on TIGIT and PD-L1 Co-Expression in Solid Tumors
Dr. Chenn has conducted research on the landscape of TIGIT and PD-L1 co-expression in solid tumors. Understanding the expression patterns of these immune checkpoint markers is essential for developing targeted therapies and improving patient outcomes in cancer immunotherapy.
Studies on HIF-1-alpha Expression
Dr. Chenn has studied the expression of HIF-1-alpha across various solid tumors. HIF-1-alpha is a protein that plays a key role in regulating responses to low oxygen levels within tumors. Insights from this research can lead to better-targeted treatments that disrupt the survival mechanisms of cancer cells.
Pre-Analytical Characterization of Cell-Free DNA
Dr. Anjen Chenn has experience in the pre-analytical characterization of cell-free DNA for liquid biopsy applications. These studies are crucial for developing non-invasive diagnostic tools that can detect cancer from blood samples, offering a less invasive alternative to traditional biopsies.
Analytical Performance of Liquid Biopsy Assays
Dr. Chenn has researched the analytical performance of contrived samples for liquid biopsy assay validation. His work in this area helps in refining the sensitivity and specificity of liquid biopsy tests, which are important for early detection and monitoring of cancer.
Detection of ctDNA Molecular Response in NSCLC
Dr. Chenn has worked on enhancing the detection of circulating tumor DNA (ctDNA) molecular response in immunotherapy-treated non-small cell lung cancer (NSCLC). His research aims to improve methods for tracking treatment effectiveness and disease progression using ctDNA markers.
Spatial Transcriptomic Studies in HNSCC
Dr. Chenn has conducted spatial transcriptomic studies of the tumor microenvironment in head and neck squamous cell carcinoma (HNSCC). These studies provide detailed insights into the spatial arrangement of gene expression within tumors, which can inform personalized treatment strategies and better understand tumor biology.